

*This announcement is for information purposes only and has not been and will not be registered as a prospectus or a statement in lieu of prospectus with any Registrar of Companies in India and is not and should not be construed as an offering circular, an offering memorandum, an advertisement, a solicitation, an offer or an offer document under the Companies Act, 2013, as amended, the Securities and Exchange Board of India (Issue of Capital Disclosure Requirements) Regulations, 2018, as amended, or any other applicable law in India, the United States or any other jurisdiction. and is not an offer to sell or the solicitation of an offer to acquire, purchase or subscribe for securities and neither this announcement nor anything herein forms the basis for any contract or commitment whatsoever.*

January 4, 2021

To,  
Dy. General Manager  
Department of Corporate Services,  
BSE Ltd.,  
P. J. Towers, Dalal Street,  
Fort, Mumbai – 400 001.

To,  
The Manager – Listing,  
The National Stock Exchange of India Ltd.,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051.

Ref: Scrip Code: 532296

Ref: Scrip Name: GLENMARK

Dear Sir,

**Re: Intimation under the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("SEBI LODR")**

This is in furtherance to our earlier letters, we wish to inform you that Glenmark Pharmaceuticals Limited ("**Company**") has issued a notice of optional redemption to the holders of U.S. \$200 million 4.5% Senior Notes due 2021 ("**Notice**") listed on the Singapore Exchange Securities Trading Limited, in accordance with the terms of the Indenture dated as of August 1, 2016 (as amended, supplemented, waived or otherwise modified from time to time), between, among others, the Company and Citicorp International Limited, as trustee. Copy of the Notice is attached herewith.

Capitalised or other terms used but not defined herein shall, unless the context otherwise requires, have the meanings as set out in the Notice.

We request you to kindly take this intimation on record and to treat the same as compliance with the applicable provisions of the SEBI LODR.

Thanking you,

Yours faithfully,  
For Glenmark Pharmaceuticals Limited



**Harish Kuber**  
Company Secretary & Compliance Officer  
Encl: as above

**Glenmark Pharmaceuticals Ltd.**

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai - 400 099, India

T: 91 22 4018 9999 F: 91 22 4018 9986 CIN No: L24299MH1977PLC019982 W: [www.glenmarkpharma.com](http://www.glenmarkpharma.com)

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: [complianceofficer@glenmarkpharma.com](mailto:complianceofficer@glenmarkpharma.com)

**NOTICE TO HOLDERS OF THE REDEMPTION  
OF US\$10,000,000 AGGREGATE PRINCIPAL AMOUNT OF THE  
4.5% SENIOR NOTES DUE 2021  
OF GLENMARK PHARMACEUTICALS LIMITED**

**Regulation S ISIN: XS1456577334; Regulation S Common Code: 1456577334**

4 January, 2021

NOTICE IS HEREBY GIVEN that, pursuant to Section 3.09 of the Indenture dated as of August 1, 2016 (as amended, supplemented, waived or otherwise modified from time to time, the "**Indenture**"), between, among others, Glenmark Pharmaceuticals Limited, a company incorporated with limited liability under the laws of the Republic of India (the "**Issuer**") and Citicorp International Limited, as trustee (the "**Trustee**"), the Issuer has elected to redeem (the "**Redemption**") US\$10,000,000 aggregate principal amount outstanding of its 4.5% Senior Notes due 2021 (the "**Notes**", and the Notes to be redeemed, the "**Redeemed Notes**") on 15 January, 2021 (the "**Redemption Date**"). The Redemption is being made pursuant to Section 3.09 of the Indenture and paragraph 7 of the Notes. Capitalised terms used herein but not otherwise defined herein shall have the meaning ascribed to it in the Indenture.

Pursuant to Section 3.09 of the Indenture, the redemption price for the Redeemed Notes will be 101.125% of the outstanding principal amount of the Redeemed Notes, plus accrued and unpaid interest thereon and Additional Amounts, if any, to, but not including, the Redemption Date, and assuming that the Redemption Date was 15 January, 2021, this will result in an aggregate payment to the holders of Redeemed Notes on the Record Date (as defined below) of US\$202,250, plus accrued and unpaid interest thereon, per US\$200,000 of Notes held (the "**Redemption Price**").

The record date on which any holder must hold any Redeemed Note to be entitled to the Redemption Price is the Business Day immediately prior to the Redemption Date - 14 January, 2021 (the "**Record Date**").

The Redeemed Notes must be surrendered to the Paying Agent, which is Citibank, N.A., London Branch, 1 North Wall Quay Dublin 1, Ireland, Attn: Agency and Trust, to collect the Redemption Price. The Notes are currently held in global form. Unless the Notes are redeemed in full, on the Redemption Date, upon surrender of such Notes, a new Note or Notes in principal amount equal to the unredeemed portion of the Notes shall be issued upon cancellation of the original Note.

Unless the Issuer defaults in making payment of the Redemption Price or the Paying Agent is prohibited from making such payment pursuant to the terms of the Indenture, interest and Additional Amounts, if any, on the Redeemed Notes shall cease to accrue on and after the Redemption Date.

No representation is made as to the correctness or accuracy of the common code or ISIN numbers listed on this Notice of Redemption or printed on the Notes.

**Glenmark Pharmaceuticals Limited**

GLENMARK PHARMACEUTICALS LIMITED



By: Kapil Kriplani  
Name: Kapil Kriplani  
Title: VP & Global head - Treasury